Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes

Manta Diane; Mbango-Ekouta Noel Désirée; Nda Mefo'o Jean Pierre; Assiene Oyong Damase Serge; Eloumou Bagnaka Servais; Adiogo Dieudonné

doi:doi:10.11648/j.ajbls.20210905.12

Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, Adiogo Dieudonné

Published in American Journal of Biomedical and Life Sciences (Volume 9, Issue 5)

Received: 2 August 2021 Accepted: 26 August 2021 Published: 11 September 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: The C-peptide assay is the more reliable indicator of insulin secretion than insulin itself, making it possible to optimize the treatment and to anticipate the evolution of complications linked to type 2 diabetes. The present study reports the relationship between the levels of C-peptide, the body mass index and the duration of type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. The aim of this study was to assess relationship between serum C-peptide levels with some patient characteristics such as duration in type 2 diabetes and obesity. Methods: We carried out an analytical cross-sectional study over a period of 9 months of patients with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. We included any patient whose diagnosis of type 2 diabetes was mentioned in the medical file. The C-peptide assays after fasting blood sampling were carried out according to the principle of electro-chemiluminescence assay. The ANOVA and PEARSON tests made it possible to compare groups and look for correlations between C-peptide and other variables. The significant threshold was set at P˂0.05. Results: We included 90 subjects with a mean age of 58±12.31 years. The average BMI was 28.18±5.51 kg/m². The mean duration of diabetes was 8.71±6.94 years, the mean C-peptide level was 2.50±1.68 ng/ml. We found that C-Peptide levels increased with body mass index (P=0.004) and patient age (P=0.004). Conversely, we found that C-peptide levels increased with duration of diabetes but not significantly (P=0.411). Conclusion: The C-peptide levels make it possible to objectify the residual secretion of pancreatic beta cells. We found that C-peptide levels increases with increasing body mass index, but they were no significant correlation between C-peptide levels and the diabetes duration.

Published in	American Journal of Biomedical and Life Sciences (Volume 9, Issue 5)
DOI	10.11648/j.ajbls.20210905.12
Page(s)	236-238
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

C-peptide, Type 2 Diabetes, Douala

References

[1]	Organisation Mondiale de la santé Rapport mondial sur le diabète, 2016. http://apps.who.int/iris/bitstream/10665/254648/1/9789242565256-fre.pdf?ua=1 (consulté le 24/09/2017).
[2]	Sauvanet J. P, Sheen A. J, Ziegler O., Drouin P., « insulino sensibilité, surcharge pondérale et diabète de type 2 » Diabetes Metab, 2001, 27, cahier 2, 189-293.
[3]	Léonel Soyeux et al. «effet of immigration in France on type 2 diabetes mellitus risk» 8 december 2003, p 31.
[4]	Chan W. B., Chan J. C., Chow C. C., Young V. T., So W. Y., Li J. K., and al. Glycaemic control in type 2 diabetes: the impact of body weight, beta-cell function and patient education QJM 2000; 93: 183-190.
[5]	Polonsky K. S. Lilly lecture 1994. The β-cell in diabetes: from molecular genetics to clinical research Diabetes 1995; 44: 705-717.
[6]	J. HAZARD, L. PERLEMUTER. Endocrinologie (ABREGES), 2e édition MASSON Paris New York Barcelone Milan Mexico Sao Paulo 1983. p 551.
[7]	Zhou S, Meng X, Wang S, Ren R, Hou W, Huang K et al. A 3- year follow up study of B-cell function in patients with early-onset type 2 diabetes; Experimental and therapeutic medicine 2016; 12: 1097-102.
[8]	Siraj ES, Reddy SSK, Scherbaum WA, Abdulkadir J, Hammel JP, Faiman C. Basal and postprandial c-peptide levels in Ethiopians with diabetes. Diabetes care 2002; 25 (3): 453-7.
[9]	Chowta MN, Adhikari PM, Chowta NK, Shenoy AK, D’Souza S. Serum c-peptide level and renal function in diabetes mellitus. Indian Journal of Nephrology, 2010; 20 (1): 25-27.
[10]	Beliakin SA, Serebrennikov VN, Shklovskii BL, Patsenko MB. C-peptide as an early diagnostic of metabolic syndrome and indicator of cardiovascular disease in patients with type 2 diabetes mellitus. Voen Med Zh 2014; 335 (10): 46-9.
[11]	Gary TCK et al. Effects of interactions between c-peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus. CMAJ 2009; 180 (9): 919-926.
[12]	www.inpes.sante.fr- le disque de calcul de l’indice de masse corporel chez l’adulte.
[13]	www.roche.com: notice C-peptide Elecsys 2013-11, V 9.0 English.
[14]	Anand Sonwane, L. Romesh Sharma, Santa Naorem, Lallan Prasad, Salam Ranabir; Fasting c-peptide level and its correlation with body mass index and duration of diabetes in type 2 diabetes.
[15]	Thunander M, Torn C, Peterson C, Ossiansson B, Fornander J, Landin-Olsson M. Levels of C-peptide, BMI, and age, and their utility for classiﬁcation of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol 2012; 166: 1021-1029.
[16]	Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107: 40-45.
[17]	Nakayama H, Kato T, Nakayama S, Kaku H, Muraishi K, Tokubuchi I, Hara K et al. Cross sectional and longitudinal analysis of factors contributing to the progressive loss of the beta cell function in type 2 diabetes mellitus. Intern Med 2015; 54 (16): 1971-6.
[18]	Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 2005; 97: 1113–1118.
[19]	Zangeneh F, Arora PS, Dyck PJ, Bekris L, Lernmark A, Achenbach SJ. Effects of duration of diabetes on insulin secretion. Endocr. Pract. 2006; 12 (4): 388-393.

Cite This Article

Plain Text BibTeX RIS

APA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. (2021). Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes. American Journal of Biomedical and Life Sciences, 9(5), 236-238. https://doi.org/10.11648/j.ajbls.20210905.12

Copy | Download

ACS Style

Manta Diane; Mbango-Ekouta Noel Désirée; Nda Mefo'o Jean Pierre; Assiene Oyong Damase Serge; Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes. Am. J. Biomed. Life Sci. 2021, 9(5), 236-238. doi: 10.11648/j.ajbls.20210905.12

Copy | Download

AMA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes. Am J Biomed Life Sci. 2021;9(5):236-238. doi: 10.11648/j.ajbls.20210905.12

Copy | Download

@article{10.11648/j.ajbls.20210905.12,
  author = {Manta Diane and Mbango-Ekouta Noel Désirée and Nda Mefo'o Jean Pierre and Assiene Oyong Damase Serge and Eloumou Bagnaka Servais and Adiogo Dieudonné},
  title = {Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {9},
  number = {5},
  pages = {236-238},
  doi = {10.11648/j.ajbls.20210905.12},
  url = {https://doi.org/10.11648/j.ajbls.20210905.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210905.12},
  abstract = {Introduction: The C-peptide assay is the more reliable indicator of insulin secretion than insulin itself, making it possible to optimize the treatment and to anticipate the evolution of complications linked to type 2 diabetes. The present study reports the relationship between the levels of C-peptide, the body mass index and the duration of type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. The aim of this study was to assess relationship between serum C-peptide levels with some patient characteristics such as duration in type 2 diabetes and obesity. Methods: We carried out an analytical cross-sectional study over a period of 9 months of patients with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. We included any patient whose diagnosis of type 2 diabetes was mentioned in the medical file. The C-peptide assays after fasting blood sampling were carried out according to the principle of electro-chemiluminescence assay. The ANOVA and PEARSON tests made it possible to compare groups and look for correlations between C-peptide and other variables. The significant threshold was set at P˂0.05. Results: We included 90 subjects with a mean age of 58±12.31 years. The average BMI was 28.18±5.51 kg/m2. The mean duration of diabetes was 8.71±6.94 years, the mean C-peptide level was 2.50±1.68 ng/ml. We found that C-Peptide levels increased with body mass index (P=0.004) and patient age (P=0.004). Conversely, we found that C-peptide levels increased with duration of diabetes but not significantly (P=0.411). Conclusion: The C-peptide levels make it possible to objectify the residual secretion of pancreatic beta cells. We found that C-peptide levels increases with increasing body mass index, but they were no significant correlation between C-peptide levels and the diabetes duration.},
 year = {2021}
}

Copy | Download

TY - JOUR
T1 - Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes
AU - Manta Diane
AU - Mbango-Ekouta Noel Désirée
AU - Nda Mefo'o Jean Pierre
AU - Assiene Oyong Damase Serge
AU - Eloumou Bagnaka Servais
AU - Adiogo Dieudonné
Y1 - 2021/09/11
PY - 2021
N1 - https://doi.org/10.11648/j.ajbls.20210905.12
DO - 10.11648/j.ajbls.20210905.12
T2 - American Journal of Biomedical and Life Sciences
JF - American Journal of Biomedical and Life Sciences
JO - American Journal of Biomedical and Life Sciences
SP - 236
EP - 238
PB - Science Publishing Group
SN - 2330-880X
UR - https://doi.org/10.11648/j.ajbls.20210905.12
AB - Introduction: The C-peptide assay is the more reliable indicator of insulin secretion than insulin itself, making it possible to optimize the treatment and to anticipate the evolution of complications linked to type 2 diabetes. The present study reports the relationship between the levels of C-peptide, the body mass index and the duration of type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. The aim of this study was to assess relationship between serum C-peptide levels with some patient characteristics such as duration in type 2 diabetes and obesity. Methods: We carried out an analytical cross-sectional study over a period of 9 months of patients with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. We included any patient whose diagnosis of type 2 diabetes was mentioned in the medical file. The C-peptide assays after fasting blood sampling were carried out according to the principle of electro-chemiluminescence assay. The ANOVA and PEARSON tests made it possible to compare groups and look for correlations between C-peptide and other variables. The significant threshold was set at P˂0.05. Results: We included 90 subjects with a mean age of 58±12.31 years. The average BMI was 28.18±5.51 kg/m2. The mean duration of diabetes was 8.71±6.94 years, the mean C-peptide level was 2.50±1.68 ng/ml. We found that C-Peptide levels increased with body mass index (P=0.004) and patient age (P=0.004). Conversely, we found that C-peptide levels increased with duration of diabetes but not significantly (P=0.411). Conclusion: The C-peptide levels make it possible to objectify the residual secretion of pancreatic beta cells. We found that C-peptide levels increases with increasing body mass index, but they were no significant correlation between C-peptide levels and the diabetes duration.
VL - 9
IS - 5
ER -

Copy | Download

Author Information

Manta Diane

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Mbango-Ekouta Noel Désirée

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Nda Mefo'o Jean Pierre

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Assiene Oyong Damase Serge

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Eloumou Bagnaka Servais

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
Adiogo Dieudonné

Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. (2021). Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes. American Journal of Biomedical and Life Sciences, 9(5), 236-238. https://doi.org/10.11648/j.ajbls.20210905.12

Copy | Download

ACS Style

Manta Diane; Mbango-Ekouta Noel Désirée; Nda Mefo'o Jean Pierre; Assiene Oyong Damase Serge; Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes. Am. J. Biomed. Life Sci. 2021, 9(5), 236-238. doi: 10.11648/j.ajbls.20210905.12

Copy | Download

AMA Style

Manta Diane, Mbango-Ekouta Noel Désirée, Nda Mefo'o Jean Pierre, Assiene Oyong Damase Serge, Eloumou Bagnaka Servais, et al. Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes. Am J Biomed Life Sci. 2021;9(5):236-238. doi: 10.11648/j.ajbls.20210905.12

Copy | Download

@article{10.11648/j.ajbls.20210905.12,
  author = {Manta Diane and Mbango-Ekouta Noel Désirée and Nda Mefo'o Jean Pierre and Assiene Oyong Damase Serge and Eloumou Bagnaka Servais and Adiogo Dieudonné},
  title = {Evaluation of C-peptide in Type 2 Diabetic Patient in Douala Cameroon: C-peptide Correlation with BMI and Duration of Diabetes},
  journal = {American Journal of Biomedical and Life Sciences},
  volume = {9},
  number = {5},
  pages = {236-238},
  doi = {10.11648/j.ajbls.20210905.12},
  url = {https://doi.org/10.11648/j.ajbls.20210905.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20210905.12},
  abstract = {Introduction: The C-peptide assay is the more reliable indicator of insulin secretion than insulin itself, making it possible to optimize the treatment and to anticipate the evolution of complications linked to type 2 diabetes. The present study reports the relationship between the levels of C-peptide, the body mass index and the duration of type 2 diabetes in two hospitals (General Hospital and Gyneco-Obstetric and Pediatric Hospital) in the city of Douala Cameroon. The aim of this study was to assess relationship between serum C-peptide levels with some patient characteristics such as duration in type 2 diabetes and obesity. Methods: We carried out an analytical cross-sectional study over a period of 9 months of patients with type 2 diabetes regularly monitored at the General Hospital and Gyneco-Obstetric and Pediatric Hospital of Douala Cameroon. We included any patient whose diagnosis of type 2 diabetes was mentioned in the medical file. The C-peptide assays after fasting blood sampling were carried out according to the principle of electro-chemiluminescence assay. The ANOVA and PEARSON tests made it possible to compare groups and look for correlations between C-peptide and other variables. The significant threshold was set at P˂0.05. Results: We included 90 subjects with a mean age of 58±12.31 years. The average BMI was 28.18±5.51 kg/m2. The mean duration of diabetes was 8.71±6.94 years, the mean C-peptide level was 2.50±1.68 ng/ml. We found that C-Peptide levels increased with body mass index (P=0.004) and patient age (P=0.004). Conversely, we found that C-peptide levels increased with duration of diabetes but not significantly (P=0.411). Conclusion: The C-peptide levels make it possible to objectify the residual secretion of pancreatic beta cells. We found that C-peptide levels increases with increasing body mass index, but they were no significant correlation between C-peptide levels and the diabetes duration.},
 year = {2021}
}

Copy | Download